SparkBioLabs (CEO Hongjoo Lee), a subsidiary of SparkLabs Group, announced on the 11th that it has officially launched as a specialized bio startup accelerator (AC) and will begin full-scale program operations.
On the 10th, at the '2025 Startup Planner Growth Summit' event of 'COMEUP 2025' held at COEX in Seoul, we received an AC registration certificate from Minister of SMEs and Startups Han Seong-sook, completing our official registration as a bio-specialized accelerator.
SparkBioLabs breaks away from the uniform support system of existing ACs, focusing on a gradual selection process, and provides customized programs tailored to each applicant's growth and technological characteristics through evaluation of each company.
The program is designed to quickly address key challenges faced by biotech startups, including proof-of-concept (PoC), clinical trials, regulatory compliance, and business expansion strategies. It will also leverage SparkLabs Group's global network, spanning the US, Singapore, Saudi Arabia, Taiwan, and Australia, to support overseas expansion and investment connections.
Currently, SparkLabs Group is supporting 11 bio and wellness startups, including Sysmex Korea, PeopleBio, and Weixen, and plans to continue fostering startups by building infrastructure, including the establishment of specialized clinical hospitals.
CEO Lee Hong-joo stated, “Bio startups face various challenges during their growth and expansion process, so it is crucial to select the necessary support measures for each stage.” He added, “We will contribute to revitalizing the domestic bio-health startup ecosystem by combining customized support with SparkLabs Group’s nurturing expertise.”
SparkBioLabs regularly recruits applications for its AC program through its official website, and plans to support the global expansion of excellent technology startups by expanding its specialized accelerating capabilities in the fields of artificial intelligence, deep tech, and bio.
You must be logged in to post a comment.